Therapeutic RNA and DNA enzymes.
Recent progress in understanding how gene products interact in the control of cell proliferation has engendered high hopes for the rational design of specific therapeutic strategies. The demonstration that certain RNA and DNA nucleic acids can enzymatically cleave mRNAs has offered the possibility of inactivating abnormal gene expression. In principle, this technology is applicable to any disease where a specific gene product can be linked to the initiation and/or perpetuation of the disease. Here, a brief description of the technology that can be useful for the design of therapeutic DNA and RNA agents capable of inducing apoptosis in cancer cells is presented. Furthermore, such agents can be a valuable tool for probing gene function.
Sioud
M
M
Institute for Cancer Research, Department of Immunology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway. mosioud@embnet.uio.no
Leirdal
M
M
D000818:Animals; D021881:DNA, Catalytic / Q000378:metabolism / Q000627:therapeutic use*; D003851:Deoxyribonucleases / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009690:Nucleic Acid Conformation; D016337:RNA, Catalytic / Q000378:metabolism / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D012260:Ribonucleases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D021881:DNA, Catalytic; D016337:RNA, Catalytic; D012333:RNA, Messenger; D003851:Deoxyribonucleases; D012260:Ribonucleases